CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome

CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome

Background: Interleukin-2 (IL-2) is the first cancer therapeutic agent with an immunomodulatory function. Although it has been experimentally proven to be effective against metastatic renal cell carcinoma and metastatic melanoma, the clinical application of high-dose IL-2 (HDIL-2) has been limited b...

Full description

Bibliographic Details
Main Authors: Songyi Park, Sunghye Lee, Dongyeop Kim, Hyejeong Kim, Young-Guen Kwon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
IL-2 immunotherapy
permeability
vascular leaky syndrome (VLS)
drug side effect
endothelial dysfunction blocker
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1242970/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1242970/full

Similar Items